McKesson Corporation stock (US58155Q1031): Q4 earnings beat with raised FY2027 guidance

McKesson Corporation reported Q4 fiscal 2026 EPS of $11.69, topping estimates by $0.13, while revenue hit $96.3B, up 6% YoY but below forecasts. Shares closed at $734.93 on NYSE May 8, 2026, after a 2.63% drop.

McKesson Corporation released its fiscal Q4 2026 earnings on May 7, 2026, posting adjusted earnings per share of $11.69, surpassing analyst consensus of $11.56 by $0.13, MarketBeat as of 05/08/2026. Quarterly revenue climbed 6.0% year-over-year to $96.30 billion, missing expectations of $101.35 billion. The company raised its FY2027 EPS guidance to $43.80-$44.60, aligning with consensus projections around $44.25.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: McKesson Corporation
• Sector/industry: Healthcare distribution and services
• Headquarters/country: United States
• Core markets: US pharmaceutical distribution
• Key revenue drivers: Prescription drugs, medical supplies
• Home exchange/listing venue: NYSE (MCK)
• Trading currency: USD

McKesson Corporation: core business model

McKesson Corporation ranks among the largest healthcare companies in North America, focusing on pharmaceutical distribution, medical-surgical supplies, and healthcare technology solutions. The firm serves pharmacies, hospitals, physicians, and health systems across the US, handling billions in annual drug distribution volume. Fiscal 2026 full-year revenue reached approximately $403 billion, roughly in line with analyst forecasts, per Simply Wall St as of recent analysis.

Its business spans three main segments: US Pharmaceutical, Prescription Technology Solutions, and International. The US Pharmaceutical segment, the largest, distributes branded and generic drugs to retail pharmacies and health systems, benefiting from steady demand in the US healthcare market relevant to American investors.

Main revenue and product drivers for McKesson Corporation

The US Pharmaceutical segment generated the bulk of revenue in fiscal 2026, driven by specialty drugs, retail national accounts, and medical groups. Full-year statutory EPS hit $38.38, 9.0% above expectations, supporting a trailing twelve-month EPS of $38.47 as reported for the period ended May 2026, MarketBeat as of 05/08/2026. Growth in biopharma and specialty medications offsets generic pricing pressures.

Technology solutions like electronic prior authorization and inventory management tools add high-margin recurring revenue. International operations contribute modestly but provide geographic diversification.

Industry trends and competitive position

The US pharmaceutical distribution sector faces margin compression from drug pricing reforms and generic shifts, yet demand remains robust due to an aging population and rising chronic disease prevalence. McKesson holds a leading position alongside peers like Cencora and Cardinal Health, leveraging scale in logistics and data analytics for competitive edge in the US market.

Why McKesson Corporation matters for US investors

As a NYSE-listed giant integral to the US healthcare supply chain, McKesson Corporation offers exposure to resilient pharmaceutical distribution amid economic cycles. Its role in delivering essential drugs to American hospitals and pharmacies underscores stability for US portfolios tracking healthcare spending, which exceeds 18% of GDP.

Conclusion

McKesson Corporation's Q4 fiscal 2026 results showed an EPS beat and raised FY2027 guidance, despite revenue missing estimates, reflecting operational resilience in healthcare distribution. Full-year figures aligned with forecasts, bolstering analyst optimism for earnings growth. Investors track upcoming quarters for sustained execution amid sector dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.